Results 111 to 120 of about 6,853,200 (317)

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. [PDF]

, 2008
BACKGROUND: Artemisinin derivatives used in recently introduced combination therapies (ACTs) for Plasmodium falciparum malaria significantly lower patient infectiousness and have the potential to reduce population-level transmission of the parasite. With
Drakeley, Chris J, Bousema, Teun, Lucy C Okell, Bousema, T, Ghani, Azra C, Drakeley Chris J, Drakeley, CJ, Christopher J M Whitty, Okell Lucy C, Bousema Teun, Okell, Lucy C, Azra C Ghani, Ghani, AC, Whitty Christopher J. M, Ghani Azra C, Teun Bousema, Whitty, Christopher JM, Okell, LC, Whitty, CJ, Christopher J. M Whitty, Chris J Drakeley   +20 more
core   +1 more source

Artificial intelligence in drug combination therapy

Briefings in Bioinformatics, 2018
AbstractCurrently, the development of medicines for complex diseases requires the development of combination drug therapies. It is necessary because in many cases, one drug cannot target all necessary points of intervention. For example, in cancer therapy, a physician often meets a patient having a genomic profile including more than five molecular ...
openaire   +2 more sources

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Consumo de medicamentos por idosos, Goiânia, Brasil

Revista de Saúde Pública
OBJETIVO: Analisar o padrão de consumo de medicamentos entre idosos e sua associação com aspectos socioeconômicos e autopercepção de saúde. MÉTODOS: Estudo de base populacional e delineamento transversal com 934 idosos de Goiânia, GO, Brasil, entre ...
Thalyta Renata Araújo Santos, Dione Marçal Lima, Adélia Yaeko Kyosen Nakatani, Lílian Varanda Pereira, Geraldo Sadoyama Leal, Rita Goreti Amaral   +5 more
doaj  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Research Progress on Nano-Drug Delivery Systems for Photothermal Cancer Therapy

International Journal of Nanomedicine
Tao Li,1 Dan Xiao,2 Yanlong Yin,3 Liwen Hu4 1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Department of Pharmacy, Jiu Xing Nephrotic Hospital of Chengdu Wuhou, Chengdu, People’s Republic of China;
Li T, Xiao D, Yin Y, Hu L
doaj  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

HSA-based multi-target combination therapy: regulating drugs’ release from HSA and overcoming single drug resistance in a breast cancer model

Drug Delivery, 2018
Multi-drug delivery systems, which may be promising solution to overcome obstacles, have limited the clinical success of multi-drug combination therapies to treat cancer.
Yi Gou, Zhenlei Zhang, Dongyang Li, Lei Zhao, Meiling Cai, Zhewen Sun, Yongping Li, Yao Zhang, Hamid Khan, Hongbing Sun, Tao Wang, Hong Liang, Feng Yang   +12 more
doaj   +1 more source